[HTML][HTML] Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
X Zhou, VE Torres - Frontiers in Molecular Biosciences, 2022 - frontiersin.org
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
[HTML][HTML] Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
X Zhou, VE Torres - Frontiers in Molecular Biosciences, 2022 - ncbi.nlm.nih.gov
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
X Zhou, VE Torres - Frontiers in molecular biosciences, 2022 - pubmed.ncbi.nlm.nih.gov
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling.
X Zhou, VE Torres - Frontiers in Molecular Biosciences, 2022 - europepmc.org
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
X Zhou, VE Torres - Frontiers in Molecular Biosciences, 2022 - mayoclinic.elsevierpure.com
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
Emerging therapies for autosomal dominant polycystic kidney disease with a focus on cAMP signaling
X Zhou, VE Torres - 2022 - agris.fao.org
Autosomal dominant polycystic kidney disease (ADPKD), with an estimated genetic
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …
prevalence between 1: 400 and 1: 1,000 individuals, is the third most common cause of end …